Sign Up
Stories
Sensorion's Gene Therapy Partnership Extension
Share
AudioCure Pharma's Hearing Technology In...
BioSenic's Progress and Patent
Biotech Advancements in Hearing Loss Tre...
Sensorion Showcases SENS-501 Therapy
Sensorion's Annual General Meeting Resul...
Sensorion's Combined Shareholders' Gener...
Overview
API
Sensorion extends partnership with Institut Pasteur to develop gene therapies for hearing loss disorders, focusing on otoferlin and GJB2 mutations.
Ask a question
How does the partnership with Institut Pasteur contribute to Sensorion's overall strategy and goals in the biotech industry?
How might the extension of the partnership impact Sensorion's position in the gene therapy field for hearing loss disorders?
What are the potential implications of developing gene therapies for hearing loss disorders caused by otoferlin and GJB2 mutations?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Oct 2023
Nov 2023
Dec 2023
Coverage